FDA halts tests of BioMarin drug amid heightened focus on gene therapy safety
Bio Pharma Dive
SEPTEMBER 7, 2021
On the heels of a two-day FDA meeting in which experts debated the risks of gene therapy, the biotech said its early-stage PKU treatment was associated with cancer in mice.
Let's personalize your content